BrainStorm to Showcase Alzheimer’s Disease Clinical Program in KOL Webinar

NEW YORKJuly 1, 2020 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, will hold a Key Opinion Leader (KOL) webinar on the Company’s Alzheimer’s disease (AD) clinical program on Wednesday July 8th at 8.15am ET. The Company recently announced that it is expanding its clinical pipeline to develop NurOwn® in AD.

The webinar will feature presentations by the two lead investigators in BrainStorm’s planned international Phase 2 trial in AD: Philip Scheltens, M.D., Ph.D., Professor of Cognitive Neurology and Director of the Alzheimer Centre at VU University Medical Center in Amsterdam, Netherlands; and Bruno Dubois, M.D., Ph.D., Professor of Neurology at the Neurological Institute of the Salpétrière University Hospital in Paris, France. The 52-week, open-label, proof-of-concept clinical trial is designed to evaluate NurOwn® in 40 participants with prodromal to mild AD. It will be conducted at VU University Medical Center (Amsterdam), Pitié-Salpêtrière Hospital (Paris), and several other clinical trial sites in the Netherlands and France.